Advances with extended and controlled release formulations of antiepileptics in the elderly

References

• Baftiu A, Feet SA, Larsson PG, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004–2015. Epilepsy Res. 2018;139:35–42.
   PubMed Web of Science ®Google Scholar
• Brandt C, May TW. Extended-release drug formulations for the treatment of epilepsy. Expert Opin Pharmacother. 2018;19:843–850.
   PubMed Web of Science ®Google Scholar
• Reed RC, Meinhold J, Dutta S, et al. What do the suffixes–XR, ER, chrono, chronosphere–really mean as it pertains to modified-release antiepileptic drugs? J Clin Pharm Ther. 2010;35:373–383.
   PubMed Web of Science ®Google Scholar
• Anderson GD, Saneto RP. Modified-release formulations of second-generation antiepileptic drugs: pharmacokinetic and clinical aspects. CNS Drugs. 2015;29:669–681.
   PubMed Web of Science ®Google Scholar
• Cowles VE, Gordi T, Hou SY. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. Clin Drug Investig. 2012;32:593–601.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Salladini C, Di Marco G, et al. Extended-release formulations in epilepsy. J Child Neurol. 2007;22:419–426.
   PubMed Web of Science ®Google Scholar
• Reed RC, Dutta S, Cavanaugh JH, et al. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Epilepsy Behav. 2006;8:391–396.
   PubMed Web of Science ®Google Scholar
• Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging. 2003;20:141–152.
   PubMed Web of Science ®Google Scholar
• Fenn HH, Sommer BR, Ketter TA, et al. Safety and tolerability of mood-stabilising anticonvulsants in the elderly. Expert Opin Drug Saf. 2006;5:401–416.
   PubMed Web of Science ®Google Scholar
• Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand. 2011;124:223–237.
   PubMed Web of Science ®Google Scholar
• Thibault M, Blume WT, Saint-Hilaire J-M, et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 2002;50:243–249.
   PubMed Web of Science ®Google Scholar
• Citrome L, Tremeau F, Wynn PS, et al. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol. 2004;24:255–259.
   PubMed Web of Science ®Google Scholar
• Smith MC, Centorrino F, Welge JA, et al. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav. 2004;5:746–751.
   PubMed Web of Science ®Google Scholar
• McCabe PH, Michel NC, McNew CD, et al. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. Epilepsy Behav. 2006;8:601–605.
   PubMed Web of Science ®Google Scholar
• Pierre-Louis SJC, Brannegan RT, Evans AT. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium. Clin Neurol Neurosurg. 2009;111:437–441.
   PubMed Web of Science ®Google Scholar
• Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos. 2004;25:345–352.
   PubMed Web of Science ®Google Scholar
• Sommerville KW, Dutta S, Biton V, et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Investig. 2003;23:661–670.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine Clinical Trials.gov. [cited 2018 20 Jul]. Available from: www.clinicaltrials.gov
   Google Scholar
• Sajatovic M, Coconcea N, Ignacio RV, et al. Adjunct extended-release valproate semisodium in late life schizophrenia. Int J Geriatr Psychiatry. 2008;23:142–147.
   PubMed Web of Science ®Google Scholar
• Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol. 2016;16:149.
   PubMed Web of Science ®Google Scholar
• Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013;84:1138–1147.
   PubMed Web of Science ®Google Scholar
• Takeshima T, Suzuki N, Matsumori Y, et al. Effectiveness and safety of an extended-release tablet of sodium valproate for the prophylactic treatment of migraine: postmarketing surveillance in Japan. Neurol Clin Neurosci. 2016;4:134–141.
   PubMed Web of Science ®Google Scholar
• Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450–459.
   PubMed Web of Science ®Google Scholar
• Stevens RE, Limsakun T, Evans G, et al. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (carbatrol and tegretol-XR). J Pharm Sci. 1998;87:1531–1534.
   PubMed Web of Science ®Google Scholar
• Wolf P, May T, Tiska G, et al. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung. 1992;42:284–288.
   PubMed Web of Science ®Google Scholar
• Sivenius J, Heinonen E, Lehto H, et al. Reduction of dosing frequency of carbamazepine with a slow-release preparation. Epilepsy Res. 1988;2:32–36.
   PubMed Web of Science ®Google Scholar
• McKee PJ, Blacklaw J, Carswell A, et al. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. Br J Clin Pharmacol. 1993;36:257–261.
   PubMed Web of Science ®Google Scholar
• Garnett WR, Levy B, McLean AM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia. 1998;39:274–279.
   PubMed Web of Science ®Google Scholar
• Mirza WU, Rak IW, Thadani VM, et al. Six-month evaluation of carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology. 1998;51:1727–1729.
   PubMed Web of Science ®Google Scholar
• Hogan RE, Garnett WR, Thadani VM. Carbatrol study group. tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. Clin Ther. 2003;25:2586–2596.
   PubMed Web of Science ®Google Scholar
• Ficker DM, Privitera M, Krauss G, et al. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology. 2005;65:593–595.
   PubMed Web of Science ®Google Scholar
• Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand. 2004;109:374–377.
   PubMed Web of Science ®Google Scholar
• Persson LI, Ben-Menachem E, Bengtsson E, et al. Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine. Epilepsy Res. 1990;6:134–140.
   PubMed Web of Science ®Google Scholar
• Canger R, Altamura AC, Belvedere O, et al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand. 1990;82:9–13.
   PubMed Web of Science ®Google Scholar
• Revankar SN, Bhatt AD, Desai ND, et al. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)–200 mg. J Assoc Physicians India. 1999;47:886–889.
   PubMedGoogle Scholar
• Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin Pharmacokinet. 1992;22:11–21.
   PubMed Web of Science ®Google Scholar
• Powell G, Saunders M, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev. 2014;(2):CD007124. Review. Update in: Cochrane Database Syst Rev 2016 Dec 8;12:CD007124.
   Web of Science ®Google Scholar
• Powell G, Saunders M, Rigby A, et al. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev. 2016 Dec 8;12:CD007124.
   PubMed Web of Science ®Google Scholar
• Saetre E, Perucca E, Isojärvi J, et al. LAM 40089 study group an international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48:1292–1302.
   PubMed Web of Science ®Google Scholar
• Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16:43–54.
   PubMed Web of Science ®Google Scholar
• Consoli D, Bosco D, Postorino P, et al. EPIC study. levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC project). Cerebrovasc Dis. 2012;34:282–289.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006;20:219–231.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Ketter TA, Weisler RH, et al. Switching from other agents to extended-release carbamazepine in acute mania. Psychopharmacol Bull. 2008;41:52–58.
   PubMedGoogle Scholar
• Huang MY. Individual bioequivalence analysis of Bertek’s PhenytekTM (1×300mg extended phenytoin sodium) versus parke-davis’ dilantin® kapseals® (3×100mg). Epilepsia. 2002;43:105.
   Google Scholar
• Rojanasthien N, Chaichana N, Teekachunhatean S, et al. Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. J Med Assoc Thai. 2007;90:1883–1893.
   PubMedGoogle Scholar
• Sattler A, Schaefer M, May TW. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Seizure. 2015;31:149–154.
   PubMed Web of Science ®Google Scholar
• Striano S, Striano P, Di Nocera P, et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res. 2006;69:170–176.
   PubMed Web of Science ®Google Scholar
• French JA, Baroldi P, Brittain ST, et al. PROSPER investigators study group. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand. 2014;129:143–153.
   PubMed Web of Science ®Google Scholar
• Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–1607.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Wendling AS. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Epilepsy Res. 2009;87:256–259.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Stefan H, Schulze-Bonhage A, et al. Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study. [Article in German]. Nervenarzt. 2012;83:1292–1299.
   PubMed Web of Science ®Google Scholar
• Chung SS, Johnson JK, Brittain ST, et al. Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR®) in adults with partial-onset seizures. Acta Neurol Scand. 2016;133:124–130.
   PubMed Web of Science ®Google Scholar
• Błaszczyk B, Czuczwar SJ. Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treat. 2010;6:145–150.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society. Neurology. 2018;91:74–81.
   PubMed Web of Science ®Google Scholar
• Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (the COMPASS study). Epilepsia. 2008;49:410–417.
   PubMed Web of Science ®Google Scholar
• Polepally AR, Remmel RP, Brundage RC, et al. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: use of stable isotope methodology. J Clin Pharmacol. 2015;55:1101–1108.
   PubMed Web of Science ®Google Scholar
• Ramey P, Osborn M, Abou-Khalil B. Conversion from immediate-release to extended-release lamotrigine improves seizure control. Epilepsy Res. 2014;108:1637–1641.
   PubMed Web of Science ®Google Scholar
• Chen C, Wright J, Gidal B, et al. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Ther Drug Monit. 2013;35:188–193.
   PubMed Web of Science ®Google Scholar
• Arif H, Svoronos A, Resor SR, et al. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia. 2011;52:1905–1913.
   PubMed Web of Science ®Google Scholar
• Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology. 2007;69:1610–1618.
   PubMed Web of Science ®Google Scholar
• Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010;19:352–358.
   PubMed Web of Science ®Google Scholar
• French JA, Temkin NR, Shneker BF, et al. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics. 2012;9:176–184.
   PubMed Web of Science ®Google Scholar
• Biton V, Shneker BF, Naritoku D, et al. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials. Clin Drug Investig. 2013;33:359–364.
   PubMed Web of Science ®Google Scholar
• Wechsler RT, Leroy R, Van Cott A, et al. Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. Epilepsy Res. 2014;108:1128–1136.
   PubMed Web of Science ®Google Scholar
• Mehta N, Bucior I, Bujanover S, et al. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes. 2016;14:54.
   PubMed Web of Science ®Google Scholar
• Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig. 2010;30:765–776.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Homery MC, Stockis A. Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects. Epilepsia. 2009;50:113.
   Web of Science ®Google Scholar
• Brodie MJ, Whitesides J, Schiemann J, et al. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016;127:114–118.
   PubMed Web of Science ®Google Scholar
• Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER study. Epilepsy Behav. 2003;4:702–709.
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, et al. VA cooperative study 428 group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868–1873.
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67:408–415.
   PubMedGoogle Scholar
• Pohlmann-Eden B. Issues when treating epilepsy in the elderly. Acta Neurol Scand Suppl. 2005;181:40–46.
   PubMedGoogle Scholar
• Dogan EA, Usta BE, Bilgen R, et al. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav. 2008;13:156‒161.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Zhuang JH, et al. Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. J Int Med Res. 2011;39:408‒415.
   Web of Science ®Google Scholar
• Ramsay RE, Uthman B, Pryor FM, et al. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia. 2008;49:1180‒1185.
   PubMedGoogle Scholar
• Groselj J, Guerrini R, Van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand. 2005;112:144‒150.
   PubMed Web of Science ®Google Scholar
• Uthman BM. Extended-release antiepilepsy drugs – review of the effects of once-daily dosing on tolerability, effectiveness, adherence, quality of life, and patient preference. US Neurol. 2014;10:30–37.
   Google Scholar
• Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, et al. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf. 2014;13:935–946.
   PubMed Web of Science ®Google Scholar
• Conway JM, Cloyd JC. Antiepileptic drug interactions in the elderly. In: Majkowski J, Bourgeois B, Patsalos P, editors. Antiepileptic drugs combination therapy and interaction. Cambridge: Cambridge University Press; 2005. p. 273–287.
   Google Scholar
• Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr. 2009;9:153‒157.
   PubMed Web of Science ®Google Scholar
• Lason W, Dudra-Jastrzebska M, Rejdak K, et al. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep. 2011;63:271–292.
   PubMed Web of Science ®Google Scholar
• Haroon M, Khan K, Thong L, et al. High prevalence of risk factors for low bone mineral density and estimated fracture and fall risk among elderly medical inpatients: a missed opportunity. Ir J Med Sci. 2018 Aug 11. [ published online]. DOI:10.1007/s11845-018-1882-2
   PubMedGoogle Scholar
• Banach M, Popławska M, Błaszczyk B, et al. Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities. Expert Opin Drug Metab Toxicol. 2016;12:1067–1080.
   PubMed Web of Science ®Google Scholar
• Chrościńska-Krawczyk M, Radzik I, Miziak B, et al. Safety considerations for patients with epilepsy taking antiepileptic drugs alongside caffeine or other methylxanthine derivatives. Expert Opin Drug Metab Toxicol. 2014;10:981–989.
   PubMed Web of Science ®Google Scholar
• Błaszczyk B, Miziak B, Czuczwar P, et al. A viewpoint on rational and irrational fixed-drug combinations. Expert Rev Clin Pharmacol. 2018;11:761–771.
   PubMed Web of Science ®Google Scholar
• Carrigan PJ, Brinker DR, Cavanaugh JH, et al. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). J Clin Pharmacol. 1990;30:743–747.
   PubMed Web of Science ®Google Scholar
• Clark AM, Pellock JM, Holmay M, et al. Clinical utility of topiramate extended-release capsules (USL255): bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. Epilepsy Behav. 2016;57:105–110.
   PubMed Web of Science ®Google Scholar